Spectral AI reports Q3 research and development revenue of $3.8 million
Spectral AI, Inc. reported Q3 research and development revenue of $3.8 million for the quarter ending September 30, 2025, down from $8.2 million in Q3 2024. Year-to-date revenue was $15.6 million, compared to $22.0 million the previous year. The company achieved a gross profit of $1.6 million for Q3 and $7.1 million for the first nine months of 2025. Cash on hand increased to $10.5 million from $3.7 million a year earlier. Spectral AI is progressing towards its De Novo FDA submission and focusing on commercializing its AI-driven diagnostic device.
Spectral AI, Inc. reported research and development revenue of $3.8 million for the third quarter ended September 30, 2025, compared to $8.2 million in the same period of 2024. Year-to-date research and development revenue was $15.6 million, down from $22.0 million for the prior year period. The company reported a gross profit of $1.6 million for the third quarter and $7.1 million for the first nine months of 2025. Cash on hand as of September 30, 2025, was $10.5 million, up from $3.7 million at the same date in 2024. During the quarter, Spectral AI continued progress toward its De Novo FDA submission and maintained focus on the commercialization of its AI-driven diagnostic device. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573619-en) on November 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
